KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Depreciation & Amortization (CF) (2016 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed Depreciation & Amortization (CF) for 13 consecutive years, with $611000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Depreciation & Amortization (CF) fell 8.26% to $611000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $2.5 million, a 0.66% decrease, with the full-year FY2025 number at $2.5 million, down 0.66% from a year prior.
  • Depreciation & Amortization (CF) was $611000.0 for Q4 2025 at Xenon Pharmaceuticals, down from $641000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $1.7 million in Q3 2023 to a low of -$629000.0 in Q4 2023.
  • A 5-year average of $473750.0 and a median of $481000.0 in 2022 define the central range for Depreciation & Amortization (CF).
  • Biggest YoY gain for Depreciation & Amortization (CF) was 384.36% in 2023; the steepest drop was 312.5% in 2023.
  • Xenon Pharmaceuticals' Depreciation & Amortization (CF) stood at $270000.0 in 2021, then rose by 9.63% to $296000.0 in 2022, then crashed by 312.5% to -$629000.0 in 2023, then surged by 205.88% to $666000.0 in 2024, then decreased by 8.26% to $611000.0 in 2025.
  • Per Business Quant, the three most recent readings for XENE's Depreciation & Amortization (CF) are $611000.0 (Q4 2025), $641000.0 (Q3 2025), and $632000.0 (Q2 2025).